Business
Allogene Therapeutics Announces June 2020 Virtual Investor Conference Participation
SOUTH SAN FRANCISCO, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering
About this update from Allogene Therapeutics, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in the following June 2020 virtual investor conferences.\n Jefferies Virtual Healthcare ConferenceJune 3, 202010:30 AM PT/1:30 PM ET Goldman Sachs 41st Annual Global Healthcare ConferenceJune 9, 20207:30 AM PT/10:30 AM ET William Blair 40th Annual Growth Stock ConferenceJune 11, 20206:40 AM PT/9:40 AM ET Raymond James 2020 Human Healthcare Innovation Conference*June 17, 20209:00AM PT/noon ET JMP Securities Hematology and Oncology ForumJune 18, 202010:00 AM PT/1:00 PM ET Webcasts will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section (https://ir.allogene.com/events). Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days. *This event will not be webcast. About Allogene TherapeuticsAllogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn. Cautionary Note on Forward-Looking Statements for AllogeneThis press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as \"predicts,\" \"believes,\" \"potential,\" \"proposed,\" \"continue,\" \"estimates,\" \"anticipates,\" \"expects,\" \"plans,\" \"intends,\" \"may,\" \"could,\" \"might,\" \"will,\" \"should\" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyse...